Tumor News and Research

RSS

AJCC Cancer Staging Manual brings together the relevant, evidence-based criteria for staging of cancer

Physicians and health care professionals around the world need a tool to facilitate the uniform description and reporting of cancer. Proper staging is essential to determine appropriate treatment, evaluate results of management and clinical trials, and to serve as the standard for local, regional and international reporting on cancer incidence and outcomes.

4 Nov 2009

Findings may lead to new drug therapies to reduce breast cancer metastasis

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.

4 Nov 2009

Radiation treatment as effective and as safe in reducing the risk of prostate cancer from returning

A shorter, five-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears to be just as effective and as safe in reducing the risk of prostate cancer from returning as standard radiation therapy, yet is delivered in two-and-a-half weeks less time, according to interim results of a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

PET imaging is not the basis for increasing dosage level

Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).

4 Nov 2009

$Optic nerve sheath meningioma patients can be cured using fractionated stereotactic radiotherapy$

Optic nerve sheath meningioma patients can be cured using fractionated stereotactic radiotherapy

Optic nerve sheath meningiomas are rare tumors that are traditionally treated with surgery, which is typically a blinding procedure. However, researchers from Thomas Jefferson University Hospital have found that a specialized type of radiation therapy offers the same local control, with fewer adverse effects on vision.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.

4 Nov 2009

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent), according to the first randomized study of its kind presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Patients dissatisfied with the way they receive results of radiology tests, wants more access to medical records

A new study by researchers at Wake Forest University School of Medicine suggests that many patients are dissatisfied with the way they receive results of radiology tests and want more access to information in their medical records, specifically, detailed, lay-language results from those tests.

3 Nov 2009

Early tolerance of proton therapy excellent in prostate cancer patients

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago.

3 Nov 2009

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

Patients with non-small cell lung cancer treated with preventative brain radiation (called prophylactic cranial irradiation or PCI), significantly decrease their risk of developing brain metastases (cancer spread in the brain) by more than 50 percent (from 18 percent to 8 percent), compared to those who did not receive the treatment, according to a randomized study presented at the plenary session November 2, 2009, at the 51st Annual Meeting of American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Pateamine A found to inhibit yet another anti-cancer mechanism

Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.

3 Nov 2009

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital.

3 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

IMC-RT does not benefit breast cancer patients

After mastectomy, breast cancer patients who receive radiation treatment to the lymph nodes located behind the breast bone do not live longer than those who do not receive radiation to this hard-to-treat area, according to a randomized 10-year study presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Tumor News and Research

AJCC Cancer Staging Manual brings together the relevant, evidence-based criteria for staging of cancer

Findings may lead to new drug therapies to reduce breast cancer metastasis

Radiation treatment as effective and as safe in reducing the risk of prostate cancer from returning

PET imaging is not the basis for increasing dosage level

Optic nerve sheath meningioma patients can be cured using fractionated stereotactic radiotherapy

Blood vessels good indicators of prostate cancer behavior

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

$3.9 million Challenge grant for Thomas Jefferson researchers

Arrowhead Research updates its shareholders

Melanoma patients treated with radiation after surgery at lower risk of cancer recurrence

Patients dissatisfied with the way they receive results of radiology tests, wants more access to medical records

Early tolerance of proton therapy excellent in prostate cancer patients

Calypso Medical Technologies presents its real-time tracking technology at 51st ASTRO annual meeting

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Pateamine A found to inhibit yet another anti-cancer mechanism

Therapy with EBV-specific CTLs effective for severely immune-compromised patients

Mechanical force switches T cell from disease-scanning to disease-fighting mode

IMC-RT does not benefit breast cancer patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News